About The Company

CCC Diagnostics was formed in 2004 by a core group of former researchers at the Johns Hopkins University. They have provided over ninety years of leadership and discovery in biophysics, oncology, and imaging. The company is located in the Caton Research Center in Baltimore, MD.



References

K. H. Tkaczuk, N. S. Tait, O. Ioffe, M. Tan, M. Mohiuddin, S. Chumsri, D. A. Van Echo, M. J. Sutula, S. Lesko, S. Deamond, P. Ts'o; Drug Response Indicator Test (DRIT) as a predictive test for treatment outcomes in advanced breast cancer patients (ABC). Clin Oncol 27:15s, 2009 (suppl; abstr 1119) – ASCO 2009.

Tkaczuk, K., Tait, NS, Rodgers, W., Tan, M., Ioffe, O., Lesko, SA, Deamond, S., Lum, ZP, Ts'o, POP. A Retrospective Study of the Drug Response Indicator Test (DRIT) as a Predictive Test for Therapeutic Outcomes of Advanced Breast Cancer Patients. 2008 San Antonio Breast Cancer Symposium, San Antonio, TX.

Company Mission

CCC Diagnostics is actively integrating discoveries in diagnostic, therapeutic, and information technologies to create innovative approaches to cancer disease management and enhance the quality of life for cancer patients. Our strategy is to provide effective, personalized chemotherapy treatment recommendations, increasing life quality and decreasing cost through appropriate drug choice.

CCC DIAGNOSTICS
Saving Lives and Life Savings

Caton Research Center
3918 Vero Road, Suite B
Baltimore, MD 21227

Phone (410) 633-4885 x1002
Fax (410) 633-4502
www.cccdiag.com

CLIA #21D1043279
Medical Lab Permit #1274
NPI #1265685440

Insurance and Medicare

CCC Diagnostics has contracted with Medicare and many national and local health plans. Verification of the patient's insurance information coverage and the contractual status of each policy is the responsibility of the ordering physician or facility prior to sample submission. For all contract billing questions, please contact Account Resolutions, LLC at (800) 799-5916.

CCC DIAGNOSTICS
Saving Lives and Life Savings

Health Professionals Brochure



DirectHit™ Test Panel for Breast Cancer

The DirectHit Test Panel for Breast Cancer can predict, with a high degree of accuracy, a tumor's responsiveness to four distinct, commonly prescribed classes of treatments (8 drugs in total). DirectHit is a diagnostic service performed on paraffin preserved tumor tissue removed during surgery. When used in combination with standard measurements, DirectHit allows physicians to avoid ineffective therapy and design an individualized chemotherapy treatment plan for each patient.

DirectHit
Test Panel for Breast Cancer

The DirectHit Test Panel for Breast Cancer is a group of molecular pharmacodiagnostic tests performed on tumor sections which detects the sensitivity or resistance of specific tumors to drug regimens. Currently, our DirectHit Test Panel for Breast Cancer is the only predictive treatment outcome test panel marketed for commonly prescribed comprehensive anti-breast cancer chemotherapy drugs.

DirectHit targets sensitivity to the following drugs: vinca alkaloids, taxanes, antiestrogens, trastuzumab and 5-fluorouracil/capecitabine. Expansion of the panel to include anthracyclines, gemcitabine, and platinum salts is in development.

DirectHit measures biomarkers linked to chemotherapy response, using fluorescent labeled antibodies to assess biomarker expression. Computerized microscopic analysis of the observed fluorescence quantitatively predicts the clinical benefit for a specific drug regimen for an individual breast cancer patient.

Sample Requirements

Each DirectHit Test Panel requires slides prepared from tumor tissue embedded in paraffin for testing. Please contact CCC Diagnostics' technical staff regarding sample preparation requirements.

(410) 633-4885 ext. 1071

Currently Available Tests:

DirectHit Test Panel for Breast Cancer

Tests in Development:

DirectHit Test Panel for Gastrointestinal Cancer

Ordering DirectHit

Physicians first establish an account with CCC Diagnostics by calling our Customer Service Line at (410) 633-4885 ext. 1002.

The DirectHit Test Panel for Breast Cancer can be scheduled by calling CCC Diagnostics' Customer Service at (410) 633-4885 ext. 1002. Once test scheduling is complete, CCC Diagnostics will send the requesting medical provider a sample kit for secure shipment of tumor slides. The turnaround time for the DirectHit Test Panel for Breast Cancer is six business days from the scheduled sample testing date.

For additional information and details on ordering the DirectHit Test Panel for Breast Cancer, call us at (410) 633-4885 ext. 1002 or visit our website at www.cccdiag.com.

The DirectHit Advantages

- Predicts efficacy of chemotherapy.
- Has quick turnaround time.
- Helps physician create individualized treatment plan.
- Improves quality of life.
  - Lessens exposure to ineffective drug treatments.
  - Reduces potential for side effects.
- Saves money.
- Approved by Medicare, Blue Cross, Blue Shield and others.

Management

Vivian Lauderdale, MS, MBA, RAC
Chief Operating Officer

Ms. Lauderdale has an MS in biochemistry from George Washington School of Medicine, an Executive MBA from the Anderson School of Management at the University of California at Los Angeles, and a Medical Regulatory Affairs Certification through the Regulatory Affairs Professionals Society. She has over twenty years of experience in medical biotechnology product development, operations, and regulatory affairs.

David A. Van Echo, M.D.
Medical Director

Dr. Van Echo received his M.D. from the University of Maryland School of Medicine. He has over thirty years of experience in oncology. Dr. Van Echo has served as the Director of Clinical Programs of the University of Maryland Cancer Center and is currently the Director of the HarborView Cancer Center of the Harbor Hospital in Baltimore, Maryland. He has served as the Medical Director for CCC Diagnostics since 2004.

Stephen A. Lesko, Ph.D.
Research Director

Dr. Lesko received his doctorate in biochemistry from the University of Maryland, Baltimore. He was a faculty member of the Johns Hopkins University School of Public Health for over twenty years and is one of the foremost authorities in microscopy. Dr. Lesko was instrumental in developing the computer-assisted imaging system for research applications at the Johns Hopkins University School of Public Health in 1981.